Have you or a loved one taken the Dupixent eczema shot and been diagnosed with cutaneous T-cell lymphoma (CTCL)? Lawsuits against Sanofi & Regeneron are exploding—over 150 cases filed in 2025 alone, plus the first wrongful-death suit this October. Discover the hidden cancer link, FDA’s new investigation, 300+ adverse reports, and how Direct2Attorney connects you to top lawyers for free. No win, no fee—claim your payout before the statute runs out!
What Is Dupixent?
Dupixent (dupilumab) is a prescription biologic medication developed by Sanofi and Regeneron, approved by the FDA in 2017 as a targeted treatment for several chronic inflammatory conditions. It works by blocking the signaling of two key proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), which play a central role in driving allergic and inflammatory responses in the body. This monoclonal antibody is administered via subcutaneous injection—typically a pre-filled syringe or pen—every two weeks after an initial loading dose, and it’s often used when topical treatments or other therapies fall short.
Common indications include:
While Dupixent has helped millions manage debilitating symptoms, its long-term safety profile continues to be studied, particularly regarding rare immune-related risks. If you’ve been prescribed Dupixent, consult your doctor about monitoring for any emerging side effects.
At Direct2Attorney, we believe in your right to justice.
Our legal specialists will review your case thoroughly to identify your options.
We will assess your eligibility and assist you in filing your case, ensuring you feel supported throughout the process.
Dupixent Cancer Link
Emerging research has raised concerns about a potential association between Dupixent use and an increased risk of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin lymphoma that primarily affects the skin. CTCL subtypes like mycosis fungoides and Sézary syndrome typically present with itchy, red patches or plaques that can progress if untreated, and while the exact mechanism isn’t fully understood, studies suggest Dupixent may “unmask” or accelerate underlying CTCL in patients initially treated for conditions like atopic dermatitis or asthma.
Key findings from recent studies include:
If you’ve experienced health issues due to Dupixent, we are here to help you secure the compensation you deserve. Contact Us
Dupixent Lawsuit Update
As of November 2025, Dupixent lawsuits are gaining momentum in the U.S., with plaintiffs alleging that manufacturers Sanofi and Regeneron failed to adequately warn about the CTCL risk despite mounting evidence from post-marketing studies. Over 150 individual cases have been filed in federal courts across states like Tennessee, California, and New York, focusing on product liability, failure-to-warn, and wrongful death claims—particularly for patients diagnosed with CTCL after prolonged use (1+ months).
Recent developments:
Patients who developed a rare skin cancer called cutaneous T-cell lymphoma (CTCL) after using Dupixent are suing the drug makers, Sanofi and Regeneron. They claim the companies knew—or should have known—about this risk but did not put a strong enough warning on the label. The lawsuits say Dupixent was prescribed for eczema, asthma, or sinus problems, and the cancer appeared months or years later.
Any man or woman who used Dupixent for 3+ months, was later diagnosed with cutaneous T-cell lymphoma (CTCL) between ages 35–75, had no prior lymphoma, and still has biopsy proof can file—no lawyer yet required.
Cutaneous T-cell lymphoma (CTCL). It often starts as itchy red patches that look like bad eczema, then thickens into plaques or tumors. Two common forms are mycosis fungoides (slow-growing) and Sézary syndrome (more aggressive). Studies show Dupixent users can be 4 times more likely to develop CTCL than people who never took the drug.
If your Dupixent lawsuit succeeds, you could receive between $50,000 and $70,000 in total compensation, covering all your past and future medical bills, lost income, and the pain of living with cutaneous T-cell lymphoma—no money has been paid out yet, but lawyers handling these cases expect settlements in this range for most patients with clear biopsy proof and strong medical records.
Every state sets its own deadline—called the “statute of limitations.” Most give you 2 years from the date you were diagnosed with CTCL. A few states allow 1 year, others up to 3. Once the deadline passes, you lose your right to sue, so contact a lawyer today to check your exact cutoff date.
Over 150 cases are active in federal courts. The first wrongful-death lawsuit was filed in October 2025 in Tennessee. Judges are talking about combining all cases into one big courtroom (called an MDL) to move faster. No trials or settlements have happened yet, but attorneys expect the first “test cases” in late 2026.
Call us or fill out the form on Direct2Attorney.com. Within 24 hours you’ll speak to an experienced Dupixent lawsuit attorney. The call and case review cost nothing, and you pay zero fees unless you win money. They will pull your records, tell you if you qualify, and file before your deadline runs out
